154 related articles for article (PubMed ID: 15900579)
1. Prevalence of types 16 and 33 is increased in high-risk human papillomavirus positive women with cervical intraepithelial neoplasia grade 2 or worse.
Bulkmans NW; Bleeker MC; Berkhof J; Voorhorst FJ; Snijders PJ; Meijer CJ
Int J Cancer; 2005 Nov; 117(2):177-81. PubMed ID: 15900579
[TBL] [Abstract][Full Text] [Related]
2. The impact of age and high-risk human papillomavirus (hrHPV) status on the prevalence of high-grade cervical intraepithelial neoplasia (CIN2+) in women with persistent hrHPV-positive, cytology-negative screening samples: a prospective cohort study.
Tidy JA; Lyon R; Ellis K; Macdonald M; Palmer JE
BJOG; 2020 Sep; 127(10):1260-1267. PubMed ID: 32279427
[TBL] [Abstract][Full Text] [Related]
3. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
4. High-risk human papillomavirus (hrHPV) E6/E7 mRNA testing by PreTect HPV-Proofer for detection of cervical high-grade intraepithelial neoplasia and cancer among hrHPV DNA-positive women with normal cytology.
Rijkaart DC; Heideman DA; Coupe VM; Brink AA; Verheijen RH; Skomedal H; Karlsen F; Morland E; Snijders PJ; Meijer CJ
J Clin Microbiol; 2012 Jul; 50(7):2390-6. PubMed ID: 22553244
[TBL] [Abstract][Full Text] [Related]
5. Attributing oncogenic human papillomavirus genotypes to high-grade cervical neoplasia: which type causes the lesion?
van der Marel J; Berkhof J; Ordi J; Torné A; Del Pino M; van Baars R; Schiffman M; Wentzensen N; Jenkins D; Quint WG
Am J Surg Pathol; 2015 Apr; 39(4):496-504. PubMed ID: 25353286
[TBL] [Abstract][Full Text] [Related]
6. Associations of Single Versus Multiple Human Papillomavirus Infections With the Prevalence of Cervical Intraepithelial Neoplasia 2/3 and Squamous Cell Carcinoma Lesions: Human Papillomavirus Type-Specific Attribution.
Zhong F; Wang T; Li W; Zhang H; Zeng X; Geisler D; Zhou X; Cong Q; Sui L; Tao X; Zhao C
Lab Invest; 2024 Apr; 104(4):100328. PubMed ID: 38237737
[TBL] [Abstract][Full Text] [Related]
7. The clinical utility of extended high-risk HPV genotyping in risk-stratifying women with L-SIL cytology: A retrospective study of 8726 cases.
Tao X; Zhang H; Zhang H; Xiao Y; Zhong F; Zhou X; Cong Q; Sui L; Zhao C
Cancer Cytopathol; 2022 Jul; 130(7):542-550. PubMed ID: 35312217
[TBL] [Abstract][Full Text] [Related]
8. Three-year longitudinal data on the clinical performance of the Abbott RealTime High Risk HPV test in a cervical cancer screening setting.
Poljak M; Oštrbenk A; Seme K; Šterbenc A; Jančar N; Vrtačnik Bokal E
J Clin Virol; 2016 Mar; 76 Suppl 1():S29-S39. PubMed ID: 26643051
[TBL] [Abstract][Full Text] [Related]
9. Risk of high-grade cervical intra-epithelial neoplasia based on cytology and high-risk HPV testing at baseline and at 6-months.
Bulk S; Bulkmans NW; Berkhof J; Rozendaal L; Boeke AJ; Verheijen RH; Snijders PJ; Meijer CJ
Int J Cancer; 2007 Jul; 121(2):361-7. PubMed ID: 17354241
[TBL] [Abstract][Full Text] [Related]
10. High-risk human papillomavirus is present in cytologically false-negative smears: an analysis of "normal" smears preceding CIN2/3.
Bulk S; Rozendaal L; Zielinski GD; Berkhof J; Daalmeijer NC; Snijders PJ; van Kemenade FJ; Meijer CJ
J Clin Pathol; 2008 Mar; 61(3):385-9. PubMed ID: 17675539
[TBL] [Abstract][Full Text] [Related]
11. POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women.
Bulkmans NW; Rozendaal L; Snijders PJ; Voorhorst FJ; Boeke AJ; Zandwijken GR; van Kemenade FJ; Verheijen RH; v Groningen K; Boon ME; Keuning HJ; van Ballegooijen M; van den Brule AJ; Meijer CJ
Int J Cancer; 2004 May; 110(1):94-101. PubMed ID: 15054873
[TBL] [Abstract][Full Text] [Related]
12. Baseline prevalence and type distribution of human papillomavirus in healthy Chinese women aged 18-25 years enrolled in a clinical trial.
Zhao FH; Zhu FC; Chen W; Li J; Hu YM; Hong Y; Zhang YJ; Pan QJ; Zhu JH; Zhang X; Chen Y; Tang H; Zhang H; Durand C; Datta SK; Struyf F; Bi D;
Int J Cancer; 2014 Dec; 135(11):2604-11. PubMed ID: 24740547
[TBL] [Abstract][Full Text] [Related]
13. Human papillomavirus type-specific 18-month risk of high-grade cervical intraepithelial neoplasia in women with a normal or borderline/mildly dyskaryotic smear.
Berkhof J; Bulkmans NW; Bleeker MC; Bulk S; Snijders PJ; Voorhorst FJ; Meijer CJ
Cancer Epidemiol Biomarkers Prev; 2006 Jul; 15(7):1268-73. PubMed ID: 16835322
[TBL] [Abstract][Full Text] [Related]
14. Prediction of cervical intraepithelial neoplasia grade 2+ (CIN2+) using HPV DNA testing after a diagnosis of atypical squamous cell of undetermined significance (ASC-US) in Catalonia, Spain.
Ibáñez R; Moreno-Crespi J; Sardà M; Autonell J; Fibla M; Gutiérrez C; Lloveras B; Alejo M; Català I; Alameda F; Casas M; Bosch FX; de Sanjosé S
BMC Infect Dis; 2012 Jan; 12():25. PubMed ID: 22280073
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of High-risk Human Papillomavirus Testing for Cervical Cancer Screening in China: A Multicenter, Open-label, Randomized Clinical Trial.
Zhang J; Zhao Y; Dai Y; Dang L; Ma L; Yang C; Li Y; Kong L; Wei L; Zhang S; Liu J; Xi M; Chen L; Duan X; Xiao Q; Abulizi G; Zhang G; Hong Y; Gao X; Zhou Q; Xie X; Li L; Niyazi M; Zhang Z; Tuo J; Ding Y; Si M; Chen F; Song L; Qiao Y; Lang J
JAMA Oncol; 2021 Feb; 7(2):263-270. PubMed ID: 33377903
[TBL] [Abstract][Full Text] [Related]
16. Human papillomavirus test with cytology triage in organized screening for cervical cancer.
Veijalainen O; Kares S; Kujala P; Tirkkonen M; Vuento R; Kholová I; Luukkaala T; Osuala V; Mäenpää J
Acta Obstet Gynecol Scand; 2016 Nov; 95(11):1220-1227. PubMed ID: 27591407
[TBL] [Abstract][Full Text] [Related]
17. Presence of koilocytosis in low-grade smears of high-risk HPV-positive women is a negative predictor for cervical intraepithelial neoplasia grade 3 or more.
Siebers AG; van der Linden H; Vedder JEM; Bekkers RLM; Melchers WLG; Bulten J
Cytopathology; 2018 Jun; 29(3):275-280. PubMed ID: 29575519
[TBL] [Abstract][Full Text] [Related]
18. Comparing triage algorithms using HPV DNA genotyping, HPV E7 mRNA detection and cytology in high-risk HPV DNA-positive women.
Luttmer R; Berkhof J; Dijkstra MG; van Kemenade FJ; Snijders PJ; Heideman DA; Meijer CJ
J Clin Virol; 2015 Jun; 67():59-66. PubMed ID: 25959161
[TBL] [Abstract][Full Text] [Related]
19. PCR-based high-risk HPV test in cervical cancer screening gives objective risk assessment of women with cytomorphologically normal cervical smears.
Rozendaal L; Walboomers JM; van der Linden JC; Voorhorst FJ; Kenemans P; Helmerhorst TJ; van Ballegooijen M; Meijer CJ
Int J Cancer; 1996 Dec; 68(6):766-9. PubMed ID: 8980181
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of high-risk human papillomavirus types and cervical squamous intraepithelial lesions in women over 30 years of age in St. Petersburg, Russia.
Shipitsyna E; Zolotoverkhaya E; Kuevda D; Nasonova V; Romanyuk T; Khachaturyan A; Orlova O; Abashova E; Kostyuchek I; Shipulina O; Anttila A; Savicheva A
Cancer Epidemiol; 2011 Apr; 35(2):160-4. PubMed ID: 20884314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
